Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

tions. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, which has completed initial Phase 1 clinical studies that provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.



Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181


Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve ri
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a premerger notification under the ... the U.S. Federal Trade Commission (FTC) relating to ... About Valeant Pharmaceuticals International, Inc. ... VRX) is a multinational specialty pharmaceutical company that ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... 2014  Abbott (NYSE: ABT) announced today that it will ... Mylan for equity ownership of a newly formed entity ... Abbott,s developed markets pharmaceuticals business, and will ... of approximately $5.3 billion based on Mylan,s closing stock ... business generated approximately $2 billion in sales in 2013. ...
Breaking Medicine Technology:Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA ), ... it has filed its Annual Report on Form 20-F with ... December 31, 2010 on April 22, 2011.  The Annual Report ... The Company will provide a hard copy of ...
... The following release is being issued by law ... Feldman & Pinto: According to two new ... Medical Journal, Bayer,s birth control pills Yaz and Yasmin, ... triple the risk of serious blood clots (known as ...
Cached Medicine Technology:Sinovac Files Annual Report on Form 20-F 2
(Date:7/14/2014)... 14, 2014 Top nutritional supplement provider ... its Quality Control and Assurance Department. As the company ... additional, highly-qualified quality assurance (QA) and quality control (QC) ... which IQ Formulations has become known. , ... decades of stellar experience and qualifications to their new ...
(Date:7/14/2014)... SingaporeA*STAR,s Bioprocessing Technology Institute (BTI) has entered into ... pharmaceutical company, Roche, to identify novel drug candidates ... partnership brings together BTI,s capabilities in novel antibody ... (mAbs) therapeutics, opening up the possibility of ... death worldwide. , The collaboration makes use ...
(Date:7/14/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... MARKETS , the global synthetic biology market is ... 2018, with a five-year compound annual growth rate ... fastest growing segment, with anticipated $9.7 billion in ... the pharmaceutical/diagnostics, chemical, energy, and agricultural industries compose ...
(Date:7/14/2014)... Botanica Day Spa announced last month ... held at the day spa in down town Clearwater, ... and other refreshments will be served as clients are ... beauty products and great deals on spa services, ... , Dermaplaning (also known as “facial shaving”) is a ...
(Date:7/14/2014)... -- Along with improving vision, cataract surgery may slow ... types of dementia, a new study suggests. Better ... said. "These preliminary results indicate that improved vision ... dementia and their loved ones, both visual and non-visual," ... and University Hospitals Case Medical Center, in Ohio. ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... SOUTH SAN FRANCISCO, Calif., May 13 Rigel Pharmaceuticals, Inc. ... Gower, the company,s chairman and chief executive officer, is scheduled ... Securities Research Conference in San Francisco on Wednesday, May 20th ... the subsequent archived recording, log on to www.rigel.com . ...
... Science Olympiad to Emphasize the Importance of Fueling Body ... you find America,s brightest young minds launching rockets, crashing ... are part of the 25th annual Science Olympiad National ... first time, the incredible edible egg, on behalf of ...
... Gastroenterologist Offers Tips for Treatment , ... San Bruno, CA (PRWEB) May ... (AGE) affect Americans each year, according to eMedicine from WebMD. ... a viral, bacterial or parasitic infection. Victims are usually hit by ...
... medical search engine will debut on 16 May 2009 at the ... , ... Budapest, Hungary (PRWEB) May 13, 2009 -- Existing ... information to consumers. WebLib CEO Endre Jofoldi notes that "the goal ...
... ( BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA ... its results for the first quarter of 2009. ... stood at 3.11 million, 9.7% up on the 1Q08 ... 4Q08.Adjusted Operating Revenues totaled R$ 1,131 million in ...
... Adding B vitamin to grain products cut congenital heart defects ... -- Since the mandatory addition of folic acid to flour, ... than a decade ago, fewer babies have been born with ... of vitamin B, has been shown to reduce neural tube ...
Cached Medicine News:Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 2Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 3Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 4Health News:When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses 2Health News:Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009 2Health News:Folic Acid Reduces Infant Heart Defects 2
Sheath Introducers with guidewires....
... design, utilizing an advanced cobalt-based ... stainless steel stents. This stronger ... for unparalleled flexibility plus optimal ... Stent Systemwith thin struts that ...
... Catheter provides support to enhance the ... adverse conditions. It gives you dependable ... your destination in cardiac interventions. It ... of clinical situations and the most ...
... Xtra, and Maximum ACT introducers represent ... specialty hemostasis introducers in the world. ... hemostasis introducers for use in interventional ... angioplasty, stenting, atherectomy, temporary pacing, endomyocardial ...
Medicine Products: